• About ApaTech
• Company Profile
• Technology
• The Science of Actifuse
• The Evidence of Actifuse
• Actifuse Clinical Case Series
• Case series 1
• Case series 2
• Case series 3
• Pipeline and Product Development

Case series 3

In a third case series by Connolly, patients with spinal trauma were fused and then assessed using plain radiographs.

Actifuse was found to be effective in the treatment of traumatic spine disorders¹.

• 62% fusion/bridging bone at 3 months, rising to 93% at 9 months
• A marked improvement in back pain, down 67% at 9 months
• A significant decrease in disability
• All patients believed surgery was worthwhile
• There were no signs of implant loosening or other complications related to surgery

Patients with traumatic spine disorders are an interesting group to evaluate. Bone fusion rates tend to decrease, with correspondingly poor pain outcomes, when additional levels are fused. In addition, smoking is known to impede bone healing and subsequent fusion. Despite this, fusion rates of 93% at 9 months demonstrate the effectiveness of Actifuse. Improvements in pain, disability, neurological and work status are further markers of success. The authors conclude that Actifuse clearly represents a suitable alternative to autograft. 

1. Connolly P et al. Treatment of traumatic spinal pathology utilizing silicated calcium phosphate graft in posterolateral fusion. A Preliminary Report. Case series.